Sagimet Biosciences Inc. (SGMT) 10-Year Financial Performance & Capital Metrics

SGMT • • Industrial / General

HealthcareBiotechnologyMetabolic & Liver DiseasesNASH & Liver Diseases

AboutSagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.Show more

Revenue $0 -100.0%
EBITDA -$46M -48.2%
Net Income -$46M -63.5%
EPS (Diluted) -1.45 +5.2%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -36.92% -20.6%
ROIC -85.05%
Debt/Equity 0.00 -29.8%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 1.3x book value

✗Weaknesses

✗Shares diluted 72.3% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-53.72%

EPS CAGR

10Y-

5Y-

3Y-

TTM-28.99%

ROCE

10Y Avg-65.61%

5Y Avg-47.56%

3Y Avg-56.5%

Latest-44.12%

Peer Comparison

NASH & Liver Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
MAZEMaze Therapeutics, Inc.	1.92B	39.81	511.70		31.18%	-33.24%	3.91%	0.14
GNFTGenfit S.A.	313.52M	6.27	209	134.56%	-14.12%	-31.42%	4.54%	0.90
GYREGyre Therapeutics, Inc.	741.77M	7.70	154	-6.78%	6.2%	4.84%		0.02
TVRDTvardi Therapeutics, Inc.	42.31M	4.51	-0.10	-65.96%	-317.54%	-63.46%
UNCYUnicycive Therapeutics, Inc.	134.75M	6.27	-1.12	-100%		-89.15%		0.10
GLTOGalecto, Inc.	38.32M	23.95	-1.29			-237.68%		0.00
IVAInventiva S.A.	1.17B	6.12	-1.73	-47.37%	-13.75%
AKBAAkebia Therapeutics, Inc.	355.59M	1.34	-4.06	-17.7%	-7.07%	-38.24%

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	2M	0
Revenue Growth %	-	-	-	-	-	-1%
Cost of Goods Sold+	88K	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-
Gross Profit+	-88K	0	0	0	2M	0
Gross Margin %	-	-	-	-	1%	-
Gross Profit Growth %	-	1%	-	-	-	-1%
Operating Expenses+	14.07M	11.4M	23.72M	31.05M	32.74M	54.45M
OpEx % of Revenue	-	-	-	-	16.37%	-
Selling, General & Admin	5.68M	3.22M	4.38M	6.14M	12.96M	16.01M
SG&A % of Revenue	-	-	-	-	6.48%	-
Research & Development	8.39M	8.18M	19.34M	24.92M	19.78M	38.44M
R&D % of Revenue	-	-	-	-	9.89%	-
Other Operating Expenses	0	0	0	0	0	0
Operating Income+	-14.16M	-11.4M	-23.72M	-31.05M	-30.74M	-54.45M
Operating Margin %	-	-	-	-	-15.37%	-
Operating Income Growth %	-	0.19%	-1.08%	-0.31%	0.01%	-0.77%
EBITDA+	-14.07M	-11.4M	-23.72M	-31.05M	-30.74M	-45.57M
EBITDA Margin %	-	-	-	-	-15.37%	-
EBITDA Growth %	-	0.19%	-1.08%	-0.31%	0.01%	-0.48%
D&A (Non-Cash Add-back)	88K	1K	0	0	0	0
EBIT	-14.2M	-11.4M	-23.72M	-31.05M	-30.74M	-45.57M
Net Interest Income+	64K	30K	26K	553K	2.86M	0
Interest Income	128K	30K	26K	553K	2.86M	0
Interest Expense	64K	0	0	0	0	0
Other Income/Expense	-102K	30K	-723K	556K	2.86M	8.89M
Pretax Income+	-14.26M	-11.37M	-24.44M	-30.5M	-27.88M	-45.57M
Pretax Margin %	-	-	-	-	-13.94%	-
Income Tax+	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%
Net Income+	-14.26M	-11.37M	-24.44M	-30.5M	-27.88M	-45.57M
Net Margin %	-	-	-	-	-13.94%	-
Net Income Growth %	-	0.2%	-1.15%	-0.25%	0.09%	-0.63%
Net Income (Continuing)	-14.26M	-11.37M	-24.44M	-30.5M	-27.88M	-45.57M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0
EPS (Diluted)+	-0.64	-0.51	-1.10	-1.38	-1.53	-1.45
EPS Growth %	-	0.2%	-1.16%	-0.25%	-0.11%	0.05%
EPS (Basic)	-0.64	-0.51	-1.10	-1.38	-1.53	-1.45
Diluted Shares Outstanding	22.17M	22.17M	22.17M	22.17M	18.19M	31.35M
Basic Shares Outstanding	22.17M	22.17M	22.17M	22.17M	18.19M	31.35M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	10.81M	68.74M	58.66M	32.79M	96.65M	152.77M
Cash & Short-Term Investments	10.21M	68.7M	56.73M	32.34M	94.9M	151.25M
Cash Only	10.21M	68.7M	56.73M	158K	75.14M	75.84M
Short-Term Investments	0	0	0	32.19M	19.76M	75.41M
Accounts Receivable	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-
Inventory	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-
Other Current Assets	58K	36K	1.51M	34K	397K	463K
Total Non-Current Assets+	345K	221K	369K	239K	73K	7.49M
Property, Plant & Equipment	318K	194K	342K	212K	73K	77K
Fixed Asset Turnover	-	-	-	-	27.40x	-
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	7.41M
Other Non-Current Assets	27K	27K	27K	27K	0	0
Total Assets+	11.16M	68.96M	59.03M	33.03M	96.72M	160.26M
Asset Turnover	-	-	-	-	0.02x	-
Asset Growth %	-	5.18%	-0.14%	-0.44%	1.93%	0.66%
Total Current Liabilities+	2.08M	1.91M	2.44M	5.28M	5.65M	4.45M
Accounts Payable	1.2M	513K	761K	1.13M	186K	1.43M
Days Payables Outstanding	4.97K	-	-	-	-	-
Short-Term Debt	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0
Other Current Liabilities	0	243K	185K	57K	556K	5K
Current Ratio	5.21x	35.99x	24.04x	6.21x	17.09x	34.30x
Quick Ratio	5.21x	35.99x	24.04x	6.21x	17.09x	34.30x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	134.4M	202.96M	214.85M	214.7M	0	0
Long-Term Debt	0	0	0	0	0	0
Capital Lease Obligations	211K	65K	224K	78K	0	0
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	134.19M	202.89M	214.63M	214.62M	0	0
Total Liabilities	136.47M	204.87M	217.29M	219.98M	5.65M	4.45M
Total Debt+	341K	210K	348K	211K	65K	78K
Net Debt	-9.87M	-68.49M	-56.38M	53K	-75.07M	-75.76M
Debt / Equity	-	-	-	-	0.00x	0.00x
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-
Interest Coverage	-221.23x	-	-	-	-	-
Total Equity+	-125.31M	-135.91M	-158.26M	-186.95M	91.06M	155.81M
Equity Growth %	-	-0.08%	-0.16%	-0.18%	1.49%	0.71%
Book Value per Share	-5.65	-6.13	-7.14	-8.43	5.01	4.97
Total Shareholders' Equity	-125.31M	-135.91M	-158.26M	-186.95M	91.06M	155.81M
Common Stock	1K	1K	1K	1K	2K	3K
Retained Earnings	-155.56M	-166.93M	-191.37M	-221.87M	-249.74M	-295.31M
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	0	0	0	-84K	30K	230K
Minority Interest	0	0	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-10.55M	-10.42M	-21.71M	-24.49M	-23.77M	-42.44M
Operating CF Margin %	-	-	-	-	-11.88%	-
Operating CF Growth %	-	0.01%	-1.08%	-0.13%	0.03%	-0.79%
Net Income	-14.26M	-11.37M	-24.44M	-30.5M	-27.88M	-45.57M
Depreciation & Amortization	1K	0	0	130K	0	0
Stock-Based Compensation	2.99M	775K	1.9M	1.88M	4.99M	5.29M
Deferred Taxes	0	0	0	0	0	0
Other Non-Cash Items	75K	104K	883K	-215K	98K	-1.11M
Working Capital Changes	645K	75K	-55K	4.21M	-978K	-1.05M
Change in Receivables	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0
Change in Payables	0	0	0	0	120K	-907K
Cash from Investing+	-27K	20K	0	-32.01M	12.58M	-61.68M
Capital Expenditures	0	0	0	0	0	0
CapEx % of Revenue	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	-27K	20K	0	0	0	0
Cash from Financing+	18.48M	68.89M	9.74M	-73K	86.17M	104.82M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	0	0	-1.06M	-85K	-3.51M	-931K
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-10.55M	-10.42M	-21.71M	-24.49M	-23.77M	-42.44M
FCF Margin %	-	-	-	-	-11.88%	-
FCF Growth %	-	0.01%	-1.08%	-0.13%	0.03%	-0.79%
FCF per Share	-0.48	-0.47	-0.98	-1.10	-1.31	-1.35
FCF Conversion (FCF/Net Income)	0.74x	0.92x	0.89x	0.80x	0.85x	0.93x
Interest Paid	136K	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-	-30.61%	-36.92%
Return on Invested Capital (ROIC)	-	-	-	-	-	-85.05%
Gross Margin	-	-	-	-	100%	-
Net Margin	-	-	-	-	-1393.8%	-
Debt / Equity	-	-	-	-	0.00x	0.00x
Interest Coverage	-221.23x	-	-	-	-	-
FCF Conversion	0.74x	0.92x	0.89x	0.80x	0.85x	0.93x
Revenue Growth	-	-	-	-	-	-100%

Frequently Asked Questions

Growth & Financials

Sagimet Biosciences Inc. (SGMT) saw revenue decline by 100.0% over the past year.

Sagimet Biosciences Inc. (SGMT) reported a net loss of $57.7M for fiscal year 2024.

Dividend & Returns

Sagimet Biosciences Inc. (SGMT) has a return on equity (ROE) of -36.9%. Negative ROE indicates the company is unprofitable.

Sagimet Biosciences Inc. (SGMT) had negative free cash flow of $44.8M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener